IDEAYA Biosciences develops precision cancer drugs aimed at the specific genetic drivers of tumors. IDYA reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 14 | Stifel | Initiated | Buy | |
| Sep 9 | Guggenheim | Maintained | Buy | |
| Sep 1 | Citizens | Reiterated | Buy | |
| Aug 5 | Truist Securities | Target lowered | Buy | |
| Aug 5 | Wedbush | Target raised | Buy |
Seasonality
How IDYA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in IDYA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IDYA is in one of them and how their past IDYA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IDYA in an article yet. Here's the latest on the wider market.
About IDEAYA Biosciences
IDEAYA Biosciences is a drug developer focused on cancer treatments that target specific genetic drivers of disease. Its most advanced program, darovasertib, is being studied for uveal melanoma, a rare eye cancer, and the company is also developing candidates that combine antibody drug conjugates with DNA damage response inhibitors for solid tumors. It works with partners including Pfizer and Servier, and its therapies are aimed at cancer patients. The company is based in South San Francisco, California.
- Headquarters
- South San Francisco, CA
- Founded
- 2015
- Website
- ideayabio.com ↗